Sarepta Therapeutics (SRPT) : Currently there are 11 street experts covering Sarepta Therapeutics (SRPT) stock. The most bullish and bearish price target for the stock is $60 and $4 respectively for the short term. The average price target of all the analysts comes to $22.27. The estimated standard deviation from the target is $17.24.
Sarepta Therapeutics (SRPT) : 3 brokerage houses believe that Sarepta Therapeutics (SRPT) is a Strong Buy at current levels. 1 Analyst considers the fundamentals to be worthy of a Buy recommendation. 5 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Sarepta Therapeutics (SRPT). Zacks Investment Research suggests a Hold with a rank of 3. 1 analysts perceive the stock to be overvalued at the existing levels, hence their call is to Sell the stock. 3 others believe that the stock has run up ahead of its fundamentals and advise a Strong Sell on the stock.The median of all the 13 Wall Street Analysts endorse the stock as a Hold with a rating of 3.
Also, Brokerage firm Wedbush reiterates its rating on Sarepta Therapeutics (NASDAQ:SRPT). In a research note issued to the investors, the brokerage major maintains price-target of $36 per share.The shares have been rated Outperform. The rating by the firm was issued on July 20, 2016.
Sarepta Therapeutics (NASDAQ:SRPT): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $25.89 and $25.59 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $26.63. The buying momentum continued till the end and the stock did not give up its gains. It closed at $26.56, notching a gain of 1.88% for the day. The total traded volume was 1,362,792 . The stock had closed at $26.07 on the previous day.
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.